8-K: QT Imaging Exceeds 2025 Revenue, Projects Strong 2026 Growth

QT Imaging Holdings, Inc. reported record 2025 revenue of $18.9 million, surpassing guidance, and affirmed 2026 revenue guidance of $39 million, driven by scanner shipments and its new QTI Cloud Platform.

Summary

• 2025 revenue reached $18.9 million, exceeding the company's guidance of $18.0 million, with a record 40 scanners shipped for the year.
• Affirmed 2026 revenue guidance of approximately $39 million, representing more than double the 2025 level, driven by distributor partnerships and the initial rollout of the QTI Cloud Platform.
• Achieved a significant reimbursement milestone with the American Medical Association's (AMA) approval of a new Category III CPT code, X579T, for 3D quantitative transmission volumetric ultrasound tomography of the breast, effective January 1, 2027.
• Received U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated configuration of the Breast Acoustic CT scanner, designed to enhance visualization and expand imaging coverage.
• Uplisted to The Nasdaq Capital Market after meeting all listing requirements, including financial, corporate governance, and regulatory criteria.
• Significantly strengthened its financial position through a private placement completed in October 2025 with gross proceeds of $18.2 million.
• Entered into strategic collaborations with Intelerad Medical Systems and Olea Medical to integrate and enhance the QTI Cloud Platform with advanced visualization, quantitative analytics, and AI-ready imaging technologies.
• Secured an exclusive distribution agreement for Breast Acoustic CT scanners and the QTI Cloud Platform in the United Arab Emirates (UAE) with Al Naghi Medical Co., committing to minimum order quantities of 43 scanners and over $24 million in revenue through 2028.
• Appointed Satrajit Misra as Chief Commercial Officer and renowned breast cancer researcher Dr. Mary W. Yamashita as Medical Advisor.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, highlighting significant revenue growth, exceeding guidance, and a clear strategic path forward with key regulatory and commercial milestones achieved. The substantial increase in cash and positive outlook for 2026 underpin a positive sentiment, despite some gross margin pressure and increased operating expenses.

Positives

• 2025 revenue of $18.9 million exceeded the company's guidance of $18.0 million.
• Record 40 Breast Acoustic CT scanners were shipped in 2025, including 17 in the fourth quarter.
• Affirmed strong 2026 revenue guidance of $39 million, representing over 100% growth from 2025.
• AMA approval of new Category III CPT code X579T, effective January 1, 2027, is a significant reimbursement milestone for broader clinical adoption.
• U.S. FDA 510(k) clearance for an updated scanner configuration enhances visualization and expands imaging coverage.
• Uplisted to The Nasdaq Capital Market, indicating compliance with higher financial and corporate governance standards.
• Successfully completed an $18.2 million private placement in October 2025, significantly strengthening the balance sheet.
• Strategic collaborations with Intelerad Medical Systems and Olea Medical advance the QTI Cloud Platform's capabilities and market reach.
• Exclusive UAE distribution agreement with Al Naghi Medical Co. guarantees minimum orders of 43 scanners and over $24 million in revenue through 2028.
• Appointment of experienced industry veterans Satrajit Misra (CCO) and Dr. Mary W. Yamashita (Medical Advisor) strengthens management and clinical expertise.
• Net loss for Q4 2025 improved to $1.4 million compared to $3.5 million for Q4 2024.
• Non-GAAP adjusted EBITDA for Q4 2025 improved to $(0.4) million compared to $(1.9) million for Q4 2024.
• Non-GAAP Adjusted EBITDA for full year 2025 improved to $(3.5) million compared to $(7.4) million for 2024.
• Net cash used in operating activities for full year 2025 decreased to $9.0 million compared to $10.0 million in 2024.
• Cash, restricted cash, and cash equivalents increased substantially to $10.5 million as of December 31, 2025, from $1.2 million as of December 31, 2024.

Negatives

• Gross margin for Q4 2025 declined to 38% from 47% in Q4 2024, primarily due to higher costs for two scanners built by a contract manufacturing partner (tariffs and other fees).
• Gross margin for full year 2025 declined to 45% from 54% in 2024, primarily due to higher costs for three scanners built by a contract manufacturing partner (tariffs and other fees).
• Total operating expenses for Q4 2025 increased 57% to $3.8 million from $2.5 million in Q4 2024, mainly due to increases in employee compensation and professional and outside service costs.
• Net loss for full year 2025 was $21.1 million, significantly higher than $9.0 million in 2024, primarily due to non-cash expenses related to debt issuance, extinguishment losses, and increases in the fair value of warrant and earnout liabilities.
• Net cash used in operating activities during Q4 2025 increased to $3.1 million compared to $1.2 million during Q4 2024, primarily due to an increase in accounts receivable.

Risks

• The ability of the company to sell and deploy QTI's Breast Acoustic CT Scanner.
• The ability to extend product offerings into new areas or products.
• The ability to commercialize technology.
• Unexpected occurrences that deter the full documentation and bring-to-market plan for products.
• Trends and fluctuations in the industry.
• Changes in demand and purchasing volume of customers.
• Unpredictability of suppliers.
• The ability to attract and retain qualified personnel and the ability to move product sales to production levels.
• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• The uncertainty of projected financial information.
• Delays caused by factors outside of the company's control.
• Changes in the ability to successfully receive purchase orders and generate revenue under existing contracts with partners and distributors.
• The ability to realize the benefits of strategic partnerships.
• The rollout of the business and the timing of expected business milestones.
• The effects of competition on the company's future business.
• The ability to obtain and access financing in the future.
• The ability to pay debt obligations as they come due.

Future Outlook

The company expects 2026 revenue to be approximately $39 million, more than double the 2025 level, driven by distributor partnerships and the initial rollout of the QTI Cloud Platform. The strategic goal is to evolve from a traditional scanner company into a SaaSand biomarker-driven medical imaging platform, expanding access to safer, more patient-friendly breast imaging while building a scalable, data-driven business that advances clinical insight and improves outcomes for women.

Management Comments

• I am proud of the transformation QT Imaging achieved over the past year. In 2025 we exceeded our revenue target, increased scanner deployments, laid the foundation for our cloud SaaS platform, expanded internationally through new distribution partnerships, and significantly strengthened our balance sheet.
• This progress reflects disciplined execution across our commercial and product strategies, and that momentum has carried into 2026 as we continue building a stronger and more scalable business.
• We recently achieved an important reimbursement milestone with approval of our first CPT code, a key step toward broader clinical adoption of QTIs Breast Acoustic CT scanner and our technology.
• Combined with our Nasdaq Capital Market relisting, new U.S. FDA and UAE regulatory clearances, and the addition of a leading breast cancer researcher as Medical Advisor, these achievements reflect the continued strengthening of QT Imagings clinical, regulatory, and commercial foundation.
• Looking ahead, we expect revenue in 2026 to be approximately $39 million, more than double the 2025 level, driven by our distributor partnerships and the initial rollout of the QTI Cloud Platform.
• As we continue evolving from a traditional scanner company into a SaaSand biomarker-driven medical imaging platform, our goal is to expand access to safer, more patient-friendly breast imaging while building a scalable, data-driven business that advances clinical insight and improves outcomes for women.

Industry Context

StockSavvy.ai notes that QT Imaging's strategic shift towards a SaaSand biomarker-driven platform aligns with broader trends in medical imaging, emphasizing data-driven insights, cloud integration, and patient-friendly solutions. The focus on radiation-free breast imaging positions the company favorably against traditional mammography, while partnerships with established players like Intelerad and Olea Medical enhance its ecosystem and competitive stance in a rapidly evolving market.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to exceeding revenue guidance, strong future outlook, uplisting to Nasdaq, and a significantly strengthened balance sheet, potentially leading to increased share value.
• Customers (Medical Facilities/Patients): Enhanced product offerings (updated scanner, QTI Cloud Platform), improved visualization, and a new CPT code for reimbursement will benefit adoption and access to safer breast imaging.
• Employees: Growth and strategic expansion may lead to increased opportunities and stability within the company.
• Distributors (NXC Imaging, Al Naghi Medical Co.): Clear revenue guidance and committed minimum order quantities provide stability and growth opportunities for distribution partners.
• Partners (Intelerad, Olea Medical): Collaborations strengthen their respective ecosystems and market reach through integrated solutions.
• Creditors: A strengthened financial position and successful capital raise improve the company's ability to meet its debt obligations.

Next Steps

• Continued building a stronger and more scalable business in 2026.
• Broader clinical adoption of Breast Acoustic CT scanner and technology following CPT code approval (effective January 1, 2027).
• Initial rollout of the QTI Cloud Platform.
• Scanner shipments to UAE distributor starting in Q2 2026.
• Conference call today, March 25, 2026, at 4:30 p.m. Eastern time to discuss results and answer questions.

Key Dates

Recommendation

The company delivered strong 2025 results, exceeding revenue guidance, and provided robust 2026 guidance projecting over 100% growth. Key strategic advancements, including FDA clearance, CPT code approval, Nasdaq uplisting, and significant international distribution agreements, position QT Imaging for accelerated adoption and market penetration. The successful $18.2 million private placement significantly strengthened the balance sheet, providing capital for continued execution. While gross margins saw a slight decline due to specific manufacturing costs, the overall trajectory towards a scalable SaaS-driven platform, coupled with improved net loss and EBITDA trends, indicates strong operational momentum and future potential. These factors collectively suggest a compelling investment opportunity.

Keywords

QT Imaging, QTI, Breast Acoustic CT, medical device, breast imaging, radiation-free, SaaS, biomarker, QTI Cloud Platform, FDA clearance, CPT code, Nasdaq, financial results, revenue guidance, distribution agreement, UAE, Intelerad, Olea Medical, investor relations